Certain weight loss injections, such as GLP-1 medicines like tirzepatide (Mounjaro) and semaglutide (Wegovy), may pose risks of various side effects, including potential impacts on the pancreas. These medications function by increasing the feeling of fullness, thereby reducing cravings and the likelihood of overeating.
Typically administered weekly through injections over an extended period, these drugs should be used for weight management in obese adults with additional weight-related health issues like hypertension or cardiovascular disease, according to NHS England guidelines. Tirzepatide is recommended for eligible individuals meeting specific criteria, while semaglutide should only be taken under the guidance of a specialist weight management service.
Although GLP-1 medicines can aid in weight loss, they are not without risks. Common side effects accompany these medications, with reports indicating that some individuals may develop acute pancreatitis, a condition characterized by sudden inflammation of the pancreas.
Acute pancreatitis can lead to various complications, including the formation of pseudocysts, necrosis, infection, and chronic pancreatitis, potentially causing permanent damage to the pancreas. The Yellow Card Biobank initiated a campaign urging individuals taking GLP-1 medications to report instances of hospitalization due to acute pancreatitis.
Dr. Alison Cave, Chief Safety Officer at the Medicines and Healthcare products Regulatory Agency (MHRA), highlighted the importance of genetic testing to prevent adverse drug reactions. The MHRA aims to identify individuals at higher risk of adverse reactions through the Yellow Card Biobank, encouraging patients to report any instances of acute pancreatitis while on GLP-1 medication.
To participate in the Yellow Card scheme, individuals can find more information on how to report incidents on their website.